Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel

Prostate Cancer

Volumn , Issue , 2011, Pages

  Francini, Filippo ^a   Pascucci, Alessandra ^a   Francini, Edoardo ^a   Bargagli, Gianluca ^a   Conca, Raffaele ^a   Licchetta, Antonella ^a   Roviello, Giandomenico ^a   Martellucci, Ignazio ^a   Chiriac, Giorgio ^a   Miano, Salvatora Tindara ^a   Marzocca, Giuseppe ^a   Manganelli, Antonio ^a   Ponchietti, Roberto ^a   Savelli, Vinno ^a   Petrioli, Roberto ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOCETAXEL; ONDANSETRON; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG TOLERABILITY; DRY EYE; DYSPNEA; EPISTAXIS; FATIGUE; FOLLOW UP; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84861702691     PISSN: 20903111     EISSN: 2090312X     Source Type: Journal    
DOI: 10.1155/2011/258689     Document Type: Article

References (34)

1. Tannock I. F., de Wit R., Berry W. R., Horti J., Pluzanska A., Chi K. N., Oudard S., Théodore C., James N. D., Turesson I., Rosenthal M. A., Eisenberger M. A., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer The New England Journal of Medicine 2004 351 15 1502 1512 (Pubitemid 39315317)
2. Petrylak D. P., Tangen C. M., Hussain M. H., Lara P. N., Jones J. A., Taplin M. E., Burch P. A., Berry D., Moinpour C., Kohli M., Benson M. C., Small E. J., Raghavan D., Crawford E. D., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer The New England Journal of Medicine 2004 351 15 1513 1520 (Pubitemid 39315318)
3. de Bono J. S., Oudard S., Ozguroglu M., Hansen S., MacHiels J. P., Kocak I., Gravis G., Bodrogi I., MacKenzie M. J., Shen L., Roessner M., Gupta S., Sartor A. O., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial The Lancet 2010 376 9747 1147 1154
4. Mathew P., DiPaola R., Taxane refractory prostate cancer Journal of Urology 2007 178 3, part 2 S36 S41 (Pubitemid 47211164)
5. Paares R. L., Garcia A. A., Bevacizumab in the management of solid tumors Expert Review of Anticancer Therapy 2007 7 4 433 445 (Pubitemid 46681799)
6. Borgstrm P., Bourdon M. A., Hillan K. J., Sriramarao P., Ferrara N., Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo Prostate 1998 35 1 1 10 (Pubitemid 28158631)
7. Ryan C. J., Lin A. M., Small E. J., Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale Urologic Oncology 2006 24 3 250 253
8. Picus J., Halabi S., Rini B., The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006 Proceeding of the American Society of Clinical Oncology 2003 22, abstract 1578
9. Di Lorenzo G., Figg W. D., Fossa S. D., Mirone V., Autorino R., Longo N., Imbimbo C., Perdon S., Giordano A., Giuliano M., Labianca R., De Placido S., Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study The European Urology 2008 54 5 1089 1096
10. Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., Rubinstein L., Verweij J., Van Glabbeke M., Van Oosterom A. T., Christian M. C., Gwyther S. G., New guidelines to evaluate the response to treatment in solid tumors Journal of the National Cancer Institute 2000 92 3 205 216 (Pubitemid 30099779)
11. Scher H. I., Halabi S., Tannock I. F., Morris M., Sternberg C. N., Carducci M. A., Eisenberger M. A., Higano C., Bubley G. J., Dreicer R., Petrylak D., Kantoff P., Basch E., Kelly W. K., Figg W. D., Small E. J., Beer T. M., Wilding G., Martin A., Hussain M., Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group Journal of Clinical Oncology 2008 26 7 1148 1159
12. Melzack R., The McGill pain questionnaire: major properties and scoring methods Pain 1975 1 3 277 299
13. De Benedittis G., Massei R., Nobili R., Pieri A., The Italian pain questionnaire Pain 1988 33 1 53 62
14. McCormack A., Hunter-Smith D., Piotrowski Z. H., Grant M., Kubik S., Kessel K., Analgesic use in home hospice cancer patients Journal of Family Practice 1992 34 2 160 164
15. Petrioli R., Pascucci A., Conca R., Chiriac G., Francini E., Bargagli G., Fiaschi A. I., Manganelli A., De Rubertis G., Barbanti G., Ponchietti R., Francini G., Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study The British Journal of Cancer 2011 104 4 613 619
16. Berthold D. R., Sternberg C. N., Tannock I. F., Management of advanced prostate cancer after first-line chemotherapy Journal of Clinical Oncology 2005 23 32 8247 8252 (Pubitemid 46211562)
17. Oh W. K., Manola J., Babcic V., Harnam N., Kantoff P. W., Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes Urology 2006 67 6 1235 1240 (Pubitemid 43818095)
18. Garmey E. G., Sartor O., Halabi S., Vogelzang N. J., Second-line chemotherapy for advanced hormone-refractory prostate cancer Clinical Advances in Hematology and Oncology 2008 6 2 118 122, 127132
19. Sternberg C. N., Satraplatin in the treatment of hormone-refractory prostate cancer The British Journal of Urology International 2005 96 7 990 994 (Pubitemid 41531400)
20. Galsky M. D., Small E. J., Oh W. K., Chen I., Smith D. C., Colevas A. D., Martone L., Curley T., DeLaCruz A., Scher H. I., Kelly W. K., Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer Journal of Clinical Oncology 2005 23 7 1439 1446
21. Petrioli R., Pascucci A., Francini E., Marsili S., Sciandivasci A., De Rubertis G., Barbanti G., Manganelli A., Salvestrini F., Francini G., Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel The British Journal of Urology International 2007 100 4 775 779 (Pubitemid 47360167)
22. Loriot Y., Massard C., Gross-Goupil M., Di Palma M., Escudier B., Bossi A., Chauchereau A., Fizazi K., The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer The European Journal of Cancer 2010 46 10 1770 1772
23. Dickson P. V., Hamner J. B., Sims T. L., Fraga C. H., Ng C. Y. C., Rajasekeran S., Hagedorn N. L., McCarville M. B., Stewart C. F., Davidoff A. M., Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy Clinical Cancer Research 2007 13 13 3942 3950 (Pubitemid 47037602)
24. Kyle A. H., Huxham L. A., Yeoman D. M., Minchinton A. I., Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors Clinical Cancer Research 2007 13 9 2804 2810 (Pubitemid 46788050)
25. Thuret R., Massard C., Gross-Goupil M., Escudier B., Di Palma M., Bossi A., De Crevoisier R., Chauchereau A., Fizazi K., The postchemotherapy PSA surge syndrome Annals of Oncology 2008 19 7 1308 1311 (Pubitemid 351911963)
26. Nelius T., Filleur S., PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy Prostate 2009 69 16 1802 1807
27. Collette L., Burzykowski T., Carroll K. J., Newling D., Morris T., Schrder F. H., Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and treatment of cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals Journal of Clinical Oncology 2005 23 25 6139 6148
28. Scher H. I., Warren M., Heller G., The association between measures of progression and survival in castrate-metastatic prostate cancer Clinical Cancer Research 2007 13 5 1488 1492 (Pubitemid 46450439)
29. Heidenreich A., Pfister D. A., Ther R., Brehmer B., Docetaxel rechallenge versus docetaxel/bevacizumab in castration-resistant prostate cancer following first-line docetaxel Journal of Clinical Oncology 2010 28 15supplement, abstract e15006
30. Ramaswamy B., Elias A. D., Kelbick N. T., Dudley A., Morrow M., Hauger M., Allen J., Rhoades C., Kendra K., Chen H. X., Gail Eckhardt S., Shapiro C. L., Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients Clinical Cancer Research 2006 12 10 3124 3129 (Pubitemid 43837360)
31. Cohn D. E., Valmadre S., Resnick K. E., Eaton L. A., Copeland L. J., Fowler J. M., Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer Gynecologic Oncology 2006 102 2 134 139 (Pubitemid 44056263)
32. Gorelik B., Ziv I., Shohat R., Wick M., Hankins W. D., Sidransky D., Agur Z., Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model Cancer Research 2008 68 21 9033 9040
33. Engels F. K., Verweij J., Docetaxel administration schedule: from fever to tears? A review of randomised studies The European Journal of Cancer 2005 41 8 1117 1126 (Pubitemid 40725569)
34. Ferretti G., Fabi A., Carlini P., Papaldo P., Felici A., Tomao S., Cognetti F., Zoledronic acid and angiogenesis Clinical Cancer Research 2007 13 22, part 1 6850